Karyopharm Therapeutics Inc. (KPTI)
NASDAQ: KPTI · Real-Time Price · USD
2.000
+0.070 (3.63%)
At close: Aug 19, 2026, 4:00 PM EDT
1.973
-0.027 (-1.37%)
After-hours: Aug 19, 2026, 4:51 PM EDT
Karyopharm Therapeutics Employees
Karyopharm Therapeutics had 228 employees as of December 31, 2025. The number of employees decreased by 51 or -18.28% compared to the previous year.
Employees
228
Change (1Y)
-51
Growth (1Y)
-18.28%
Revenue / Employee
$643,075
Profits / Employee
-$985,702
Market Cap
45.36M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 228 | -51 | -18.28% |
| Dec 31, 2024 | 279 | -46 | -14.15% |
| Dec 31, 2023 | 325 | -60 | -15.58% |
| Dec 31, 2022 | 385 | -57 | -12.90% |
| Dec 31, 2021 | 442 | 10 | 2.31% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Metagenomi Therapeutics | 118 |
| Aligos Therapeutics | 82 |
| Seres Therapeutics | 66 |
| Veru Inc. | 20 |
| Filana Therapeutics | 20 |
| Context Therapeutics | 15 |
| CervoMed | 15 |
| Nutriband | 13 |
KPTI News
- 2 days ago - Karyopharm reports Q2 EPS ($2.32) vs. ($4.32) last year - TheFly
- 6 days ago - Karyopharm Therapeutics Earnings Call Transcript: Q2 2026 - Transcripts
- 6 days ago - Karyopharm Therapeutics Earnings release: Q2 2026 - Filings
- 6 days ago - Karyopharm Therapeutics Quarterly report: Q2 2026 - Filings
- 6 days ago - Karyopharm Therapeutics Slides: Q2 2026 - Filings
- 6 days ago - Karyopharm Reports Second Quarter 2026 Financial Results and Highlights Continued Progress Toward Myelofibrosis sNDA Submission - PRNewsWire
- 9 days ago - Karyopharm to Report Second Quarter 2026 Financial Results on August 13, 2026 - PRNewsWire
- 16 days ago - Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire